---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-033015"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:52:28.555360+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio reports FY2023 net loss of $51.6M; cash drops to $7.0M; MB-106 data positive

## Summary
- Cash and cash equivalents $7.0M at Dec 31, 2023, down from $76.7M at Dec 31, 2022; $30.4M debt termination payment in 2023.
- Net loss $51.6M ($6.00/share) vs $77.5M ($10.09/share) in 2022; R&D spend $40.5M vs $62.5M.
- MB-106 Phase 1/2 multicenter trial: 100% ORR in FL (n=5 all CR) and WM (n=3 with VGPR/PR); no severe CRS/ICANS.
- Registrational trial in Waldenstrom macroglobulinemia planned H2 2024; topline expected H2 2026; RMAT designation request H1 2024.
- Closed uBriGene asset sale for $6M upfront; $5M contingent; lease assignment subject to CFIUS review.

## SEC filing metadata
- accession: 0001104659-24-033015
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000110465924033015/0001104659-24-033015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000110465924033015/tm248266d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-033015
- JSON: https://secwatch.observer/filing/0001104659-24-033015.json
- Plain text: https://secwatch.observer/filing/0001104659-24-033015.txt

## Key facts
- Earnings Releases
  MUSTANG BIO, INC. reported the fiscal year ended December 31, 2023 results: net income $51.6 million, EPS $6.00 per share.
  - Period: the fiscal year ended December 31, 2023
  - Net income: $51.6 million
  - EPS: $6.00 per share
  - Result: reported results
  source text: On March 11, 2024, Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680048/000110465924033015/0001104659-24-033015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.